Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy

Triple negative breast cancer (TNBC) is an aggressive malignancy for which chemotherapy remains the standard treatment. However, between 3 and 5 years after chemotherapy, about half patients will relapse and it is essential to identify vulnerabilities of cancer cells surviving neoadujuvant therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Winter, Marie, Nait Eldjoudi, Amina, Guette, Catherine, Hondermarck, Hubert, Bourette, Roland P., Fovez, Quentin, Laine, William, Ghesquiere, Bart, Adriaenssens, Eric, Kluza, Jérôme, Le Bourhis, Xuefen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661600/
https://www.ncbi.nlm.nih.gov/pubmed/37956532
http://dx.doi.org/10.1016/j.neo.2023.100949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661600/
https://www.ncbi.nlm.nih.gov/pubmed/37956532
http://dx.doi.org/10.1016/j.neo.2023.100949

Ejemplares similares